Name | Selonsertib |
---|---|
Synonyms |
selonsertib
Benzamide, 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-4-methyl-N-[6-[4-(1-methylethyl)-4H-1,2,4-triazol-3-yl]-2-pyridinyl]- UNII:NS3988A2TC 5-(4-Cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-[6-(4-isopropyl-4H-1,2,4-triazol-3-yl)-2-pyridinyl]-4-methylbenzamide GS-4997 |
Description | Selonsertib is an apoptosis signal-regulating kinase 1 (ASK1) inhibitor with a pIC50 of 8.3±0.07. |
---|---|
Related Catalog | |
Target |
ASK1:8.3 (pIC50) |
In Vitro | Selonsertib (GS-4997) is a clinical stage ASK1 inhibitor, which has been evaluated as an experimental treatment for diabetic nephropathy and kidney fibrosis[1]. Selonsertib (GS-4997) is a highly selective and potent once-daily oral ASK1 inhibitor that competes with ATP in the ASK1 catalytic kinase domain[2]. |
References |
Density | 1.4±0.1 g/cm3 |
---|---|
Molecular Formula | C24H24FN7O |
Molecular Weight | 445.492 |
Exact Mass | 445.202637 |
LogP | 3.17 |
Index of Refraction | 1.704 |
Storage condition | -20℃ |